<div id="readability-page-1"><div><p>Agios Pharmaceuticals (AGIO) just posted its FY 2025 third quarter numbers, with revenue of US$12.9 million, basic EPS of a US$1.78 loss, and a net income loss of US$103.4 million. The trailing twelve month figures show revenue of US$44.8 million and a net loss of US$401.3 million. The company’s quarterly revenue moved from US$8.6 million in Q2 2024 to US$12.9 million in Q3 2025, while basic EPS shifted from US$16.65 in Q3 2024, driven by a one-off gain, to consistent losses across recent quarters. This puts the focus on how efficiently Agios is converting its top line into sustainable margins.</p> <p>See our full analysis for Agios Pharmaceuticals.</p><p>With the headline numbers set, the next step is to weigh them against the dominant stories around Agios, to see which narratives about growth and risk line up with the results and which ones the latest margins begin to challenge.</p> <p>See what the community is saying about Agios Pharmaceuticals</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f33953ab-776a-402a-84dd-3b05551cb62b/chart/earnings-and-revenue-history?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f33953ab-776a-402a-84dd-3b05551cb62b/chart/earnings-and-revenue-history"/><figcaption>NasdaqGS:AGIO Earnings &amp; Revenue History as at Feb 2026</figcaption></figure> <h2>US$401.3m loss over last 12 months</h2> <ul> <li>On a trailing twelve month basis, Agios reported total revenue of US$44.8 million against a net loss of US$401.3 million, and Q3 FY 2025 alone carried a US$103.4 million loss on US$12.9 million of revenue.</li> <li>Consensus narrative talks a lot about future revenue streams from PYRUKYND and other rare disease assets, yet the latest numbers still show a business that is heavily loss making:     <ul> <li>Across the last four reported quarters, net loss sat between about US$89 million and US$112 million per quarter, even as quarterly revenue ranged from US$8.7 million to US$12.9 million.</li> <li>That mix of modest revenue and large losses lines up with the view that high R&amp;D and SG&amp;A spending is weighing on margins, which is exactly what the consensus narrative flags as a key risk to earnings stability.</li> </ul> </li> </ul> <h2>Revenue forecasts vs 36.5x P/S</h2> <ul> <li>Agios is on a P/S of 36.5x compared with 11.6x for the US Biotechs industry and 6.4x for peers, while revenue is forecast to grow at 49.1% per year according to the analysis data.</li> <li>Bulls point to that 49.1% forecast revenue growth and the US$136.04 DCF fair value as support for paying a premium multiple, but the current results keep the debate alive:     <ul> <li>The trailing twelve month revenue base of US$44.8 million is still small relative to the current market value implied by a P/S far above industry and peers, so a lot of that growth story is not yet reflected in reported sales.</li> <li>At the same time, the DCF fair value of US$136.04 versus a share price of US$28.07 is a very large gap, which aligns with bullish arguments that the market is pricing the stock below long term cash flow estimates, even as simple sales multiples look expensive.</li> </ul> </li> </ul><p> On these numbers, bulls argue the rich 36.5x P/S might still be too low if forecast growth and pipeline catalysts play out as expected, while skeptics focus on the long loss-making track record and small current revenue base. <strong>🐂 Agios Pharmaceuticals Bull Case</strong></p><h2>Unprofitable today and not forecast to turn profitable soon</h2> <ul> <li>The company recorded basic EPS of a US$1.78 loss in Q3 FY 2025, and on a trailing twelve month basis EPS is a US$6.96 loss, with analysis data stating it is not forecast to reach profitability over the next three years.</li> <li>Bears argue that persistent losses and the lack of near term profitability targets make the stock risky even at US$28.07, and the latest earnings give them plenty to point to:     <ul> <li>Net losses across the last four quarters have stayed in a tight band around US$90 million to just over US$110 million per quarter, which fits the bearish concern that high spending relative to current revenue could continue for several years.</li> <li>Forecasts still assume the business remains loss making for at least three more years, so even with strong revenue growth expectations, the current earnings profile does not yet contradict the cautious view on profitability risk.</li> </ul> </li> </ul><p> For anyone weighing those bearish concerns against the growth story, it helps to see how skeptics frame the same data you are looking at. <strong>🐻 Agios Pharmaceuticals Bear Case</strong></p><h2> Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Agios Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>See the numbers differently? If this earnings story sparks a different angle for you, shape it into your own narrative in just a few minutes and Do it your way</p> <p>A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.</p> <h2>See What Else Is Out There</h2> <p>Agios is still posting large losses on a small revenue base, with no near term profitability expected and earnings heavily pressured by spending.</p> <p>If that earnings profile feels too risky for your taste, shift your attention to 84 resilient stocks with low risk scores and quickly spot companies where the risk score looks far more comfortable.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

AGIO

<p>Agios Pharmaceuticals reported a Q3 FY 2025 loss of $103.4 million on revenue of $12.9 million, reinforcing concerns about its profitability. The company has a trailing twelve-month revenue of $44.8 million and a net loss of $401.3 million. Despite a forecasted revenue growth of 49.1% per year, the high P/S ratio of 36.5x raises questions about its valuation. Analysts predict Agios will remain unprofitable for at least three more years, leading to a bearish outlook amid ongoing losses and high spending.</p>

Agios Pharmaceuticals Q3 Loss Of US$103.4m Reinforces Bearish Profitability Narratives